Tonix Pharmaceuticals (TNXP) Stock Price, News & Analysis

Company Overview

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing therapies and vaccines for conditions involving the central nervous system, immunology, and infectious diseases. The company’s programs use a range of approaches, including small-molecule medicines, biologics, vaccines, and intranasal therapies.

Tonix’s development portfolio has included TNX-102 SL, a sublingual formulation of cyclobenzaprine investigated for fibromyalgia and other pain-related conditions. The company has also pursued candidates such as TNX-1900, an intranasal oxytocin-based therapy being studied for neuropsychiatric and metabolic disorders, as well as vaccine programs including TNX-801, a vaccine candidate for smallpox and mpox.

Founded in 2007, Tonix Pharmaceuticals is headquartered in Chatham, New Jersey. The company’s research and development activities are primarily conducted in the United States, with programs intended for potential use in global markets. Seth Lederman, M.D., is the company’s founder, chairman, and chief executive officer.

Key Stats

• Today's Range: $10.80 to $11.47
• 50-Day Range: $9.51 to $14.10
• 52-Week Range: $9.40 to $28.42
• Volume: 807,907 shs
• Average Volume: 402,583 shs
• Market Capitalization: $186.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.50
• Consensus Rating: Buy

Tonix Pharmaceuticals Stock Analysis - MarketRank™

Tonix Pharmaceuticals scored higher than 83% of companies evaluated by MarketBeat, and ranked 80th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

Tonix Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Tonix Pharmaceuticals has a consensus price target of $24.50, representing about 125.4% upside from its current price of $10.87.

Amount of Analyst Coverage

Tonix Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Tonix Pharmaceuticals are expected to grow in the coming year, from ($9.90) to ($6.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tonix Pharmaceuticals is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tonix Pharmaceuticals is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tonix Pharmaceuticals has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

18.46% of the float of Tonix Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Tonix Pharmaceuticals has a short interest ratio ("days to cover") of 6.37.

Change versus previous month

Short interest in Tonix Pharmaceuticals has recently decreased by 8.98%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tonix Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Tonix Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.39

News Sentiment

Tonix Pharmaceuticals has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Tonix Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

Only 6 people have searched for TNXP on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

MarketBeat Follows

7 people have added Tonix Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.

Company Ownership

• Score: 4.4 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Tonix Pharmaceuticals in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $40,180.00 in company stock, which represents 0.0216% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Tonix Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $40,180.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

2.00% of the stock of Tonix Pharmaceuticals is held by insiders.

Percentage Held by Institutions

82.26% of the stock of Tonix Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 9/19/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TNXP
• CIK: 1430306
• Web: www.tonixpharma.com
• Phone: (862) 799-8599
• Fax: 212-923-5700
• Employees: 142
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Tonix Pharmaceuticals: $24.50
• High Price Target: $27.00
• Low Price Target: $22.00
• Potential Upside/Downside: +125.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($12.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$124.02 million
• Net Margins: -548.64%
• Pretax Margin: -548.64%
• Return on Equity: -68.99%
• Return on Assets: -61.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.61
• Quick Ratio: 6.46

Sales & Book Value

• Annual Sales: $13.11 million
• Price / Sales: 14.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $19.17 per share
• Price / Book: 0.57

Miscellaneous

• Outstanding Shares: 17,150,000
• Free Float: 16,808,000
• Market Cap: $186.42 million
• Optionable: Not Optionable
• Beta: 1.74